Accounting for technical, ethical, and political factors in priority setting

Health Systems and Reform

Volumn 2, Issue 1, 2016, Pages 51-60

  Kieslich, Katharina ^a   Bump, Jesse B ^b   Norheim, Ole Frithjof ^c   Tantivess, Sripen ^d   Littlejohns, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Cancer drugs fund; Ethics; HLA B*1502 screening; Politics; Priority setting

Indexed keywords

EID: 85024475377     PISSN: 23288604     EISSN: 23288620     Source Type: Journal    
DOI: 10.1080/23288604.2016.1124169     Document Type: Article

References (63)

1. Lasswell HD. Politics: who gets what, when, how. New York: Whittlesey House; 1936.
2. Roberts M, Hsiao W, Berman P, Reich M. Getting health reform right: a guide to improving performance and equity. New York: Oxford University Press; 2004.
3. Coulter A, Ham C, eds. The global challenge of health care rationing. Buckingham, UK: Open University Press; 2000.
4. Bump JB, Reich MR, Johnson AM. Diarrhoeal diseases and the global health agenda: measuring and changing priority. Health Policy Plan 2012; 28(8): 799-808.
5. Gilson L, Erasmus E, Borghi J, Macha J, Kamuzora P, Mtei G. Using stakeholder analysis to support moves towards universal coverage: lessons from the SHIELD project. Health Policy Plan 2012; 27(Suppl 1): i64-i76.
6. Shiffman J, Beer T, Wu Y. The emergence of global disease control priorities. Health Policy Plan 2002; 17(3): 225-234.
7. Reich MR. The politics of agenda setting in international health: child health versus adult health in developing countries. J Int Dev 1995; 7(3): 489-502.
8. Coulter A, Ham C, eds. The global challenge of health care rationing. Buckingham: Open University Press; 2000.
9. Kanavos P, Nicod E, van den Aardweg S, Pomedli, S. The impact of health technology assessments: an international comparison. Euro Observer: Health Policy Bull Eur Observ Health Syst Policies 2010; 12(4): 1-17.
10. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329 (7459): 224-7.
11. Coulter A, Ham C, eds. The global challenge of health care rationing. Buckingham: Open University Press; 2000.
12. Kieslich K. Paradigms in operation: pharmaceutical benefit assessments in England and Germany. 2015. Available at http://discov ery.ucl.ac.uk/1463556/1/PhD_Thesis_K_Kieslich_17.03.2015. pdf (accessed 23 September 2015)
13. Daniels N. Health-care needs and distributive justice. Philos Public Aff 1981; 10(2): 146-177.
14. Daniels N. Just health care. New York: Cambridge University Press; 1985.
15. Kamm FM. Equal treatment and equal chances. Philos Public Aff 1985; 14(2): 177-194.
16. Williams A. Ethics and efficiency in the provision of health care. In: Philosophy and medical welfare, Bell M, Mendus S, eds. Cambridge: Cambridge University Press; 1988; 111-126.
17. Menzel PT. Strong medicine. The ethical rationing of medical care. New York: Oxford University Press; 1990.
18. Norheim OF. Clinical priority setting. BMJ 2008; 337(7675): a1846.
19. Brock D, Wikler D. Ethical issues in resource allocation, research, and new product development. In: Disease control priorities in developing countries, 2nd ed., Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Prabhat J, Mills A, Musgrove P, eds. New York: Oxford University Press and The World Bank; 2006; 259-270.
20. Norheim OF, Baltussen R, Johri M, Chisholm D, Nord E, Brock DW, Carlsson P, Cookson R, Daniels N, Danis M, et al. Guidance on priority setting in health care (GPS Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour Alloc 2014; 12: 18.
21. World Health Organization. Making fair choices on the path to universal health coverage. Final report of the WHO Consultative Group on Equity and Universal Health Coverage. 2014. Available at http://apps.who.int/iris/bitstream/10665/112671/1/9789241507158_eng. pdf?ua=1 (accessed 23 September 2015)
22. Rawls J. Political liberalism. New York: Columbia University Press; 1993.
23. Holm S. The second phase of priority setting. Goodbye to the simple solutions: the second phase of priority setting in health care. BMJ 1998; 317(7164): 1000-1002.
24. Norheim OF. Healthcare rationing—are additional criteria needed for assessing evidence based clinical practice guidelines? BMJ 1999; 319(7222): 1426-1429.
25. Daniels N, Sabin JE. Setting limits fairly: learning to share resources for health, 2nd ed. Oxford: Oxford University Press; 2008.
26. Daniels N. Just health: meeting health needs fairly. Cambridge: Cambridge University Press; 2008.
27. Reichenbach L. The politics of priority setting for reproductive health: breast and cervical cancer in Ghana. Reprod Health Matters 2002; 10(20): 47-58.
28. Reich MR. The politics of health sector reform in developing countries: three cases of pharmaceutical policy. Health Policy 1995; 32(1–3): 47-77.
29. Jacob L, Marmor T, Oberlander J. The Oregon health plan and the political paradox of rationing: what advocates and critics have claimed and what Oregon did. J Health Polit Policy Law 1999; 24(1): 161-180.
30. Klein R, Redmayne S. Patterns of priorities. A study of the purchasing and rationing policies of health authorities. Bath: University of Bath, Centre for the Analysis of Social Policy; 1994.
31. Klein R, Day P, Redmayne S. Managing scarcity. Priority setting and rationing in the National Health Service. Buckingham: Open University Press; 1996.
32. Ham C. Tragic choices in health care: lessons from the child B case. BMJ 1999; 319(7219): 1258-1261.
33. Mossialos E, Walley T, Mrazek M. Regulating pharmaceuticals in Europe: an overview. In: Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality, Mossialos E, Mrazek M, Walley T, eds. Maidenhead: Open University Press; 2004; 1-38.
34. Walker P, Batty D. Patients protest after kidney cancer drugs rejected. 2008. Available at http://www.theguardian.com/soci ety/2008/aug/27/health.cancer (accessed 20 July 2014)
35. Klein R. Dimensions of rationing: who should do what? BMJ 1993; 307(6899): 309-11.
36. Chamberlain C, Hollingworth W. Where is the evidence for the existence of the Cancer Drugs Fund? BMJ 2014; 349: g5901.
37. Teerawattananon Y, Tritasavit N, Suchonwanich N, and Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes 2014; 108(7): 397-404.
38. National Medicines Policy Committee. National list of essential medicines, B.E. 2556 (A.D. 2013). Bangkok, Thailand: National Medicines Policy Committee; 2013.
39. Drug Information Center. Adverse drug reactions. Bangkok, Thailand: Chulalongkorn Hospital; 2015.
40. Mohara A, Youngkong S, Velasco RP, Werayingyong P, Pachanee K, Prakongsai P, Tantivess S, Tangcharoensathien V, Lertiendumrong J, Jongudomsuk P, et al. Using health technology assessment for informing coverage decisions in Thailand. J Comp Eff Res 2012; 1(2): 137-146.
41. Thailand Association for the Study of Pain. Clinical practice guideline for neuropathic pain. Bangkok, Thailand: Thailand Association for the Study of Pain; 2008.
42. The Epilepsy Society of Thailand. Clinical practice guidelines for epilepsy. Bangkok, Thailand: The Epilepsy Society of Thailand; 2010.
43. Lim K, Kwan P, Tan C. Association of HLA-B*1502 allele and carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Asia 2008; 13(1): 15-21.
44. Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Mahasirimongkol S, Teerawattananon Y. Economic evaluation of HLA-B*1502 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia 2013; 54 (9): 1628-1638.
45. Subcommittee for Benefit Package Development. Meeting minutes, 19 November 2014. Nonthaburi, Thailand: National Health Security Office; 2014.
46. Tantivess S, Perez Velasco R, Yothasamut J, Mohara A, Lim-prayoonyong H, Teerawattananon Y. Efficiency or equity? Value judgments in coverage decisions in Thailand. J Health Organ Manag 2012; 26(3): 331-342.
47. National Health Security Act. B.E. 2545 (A.D. 2002).
48. Tantivess S. Social and ethical analysis in health technology assessment. J Med Assoc Thailand 2014; 97(5): S81-S86.
49. World Health Organization. What is universal health coverage? 2015. Available at http://www.who.int/health_financing/universal_coverage_definition/en/(accessed 21 August 2015)
50. World Health Organization. The world health report 2000— health systems: improving performance. Geneva: The World Health Organization; 2000.
51. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. Available at https://www.nice.org.uk/article/pmg9/resources/non-guid ance-guide-to-the-methods-of-technology-appraisal-2013-pdf (accessed 16 November 2015)
52. Rid A, Littlejohns P, Wilson J, Rumbold B, Kieslich K, Weale A. The importance of being NICE. J R Soc Med 2015; 108 (10): 385-389.
53. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. 2009. Available at https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-p aper2 (accessed 28 October 2015)
54. NHS England. The Cancer Drugs Fund. 2015. Available at http://www.england.nhs.uk/ourwork/pe/cdf/(accessed 1 October 2015).
55. National Audit Office. Investigation into the Cancer Drugs Fund. 2015. Available at https://www.nao.org.uk/wp-content/uploads/2015/09/Investigation-into-the-Cancer-Drugs-Fund1.pdf (accessed 28 October 2015)
56. NHS England. Future of the Cancer Drugs Fund (CDF). 2015. Available at https://www.england.nhs.uk/wp-content/uploads/2015/07/item-8-cancer-drug-fund.pdf (accessed 27 October 2015)
57. NHS England. Cancer Drugs Fund consultation. 2015. Available at https://www.engage.england.nhs.uk/consultation/cdf-consultation (accessed 19 November 2015)
58. Jack A. Which way now for the Cancer Drugs Fund? BMJ 2014; 349(7974): g5524.
59. The Cancer Drugs Fund—benign or malignant? The Economist; 2015. Available at http://www.economist.com/node/21640343/print (accessed 25 August 2015)
60. Department of Health and Prime Minister’s Office. Prime Minister announces £400 million package to boost research and treatment for cancer, and a new partnership to help map genomes [Press release]. 28 September 2013. Available at https://www.gov.uk/gov ernment/news/thousands-of-patients-to-benefit-from-400-million-cancer-package (accessed 27 August 2015)
61. Gallagher J. Labour pledges cancer therapy fund. 2014. Available at http://www.bbc.co.uk/news/health-30385594 (accessed 29 October 2015)
62. Cook C. NHS England push to rein in cancer drug prices. 2014. Available at http://www.bbc.co.uk/news/health-28938022 (accessed 28 August 2015)
63. Health and Social Care Act 2012 (2012).